Hollis-Eden Radioprotectant Could Be Accelerated By Military Interest
Executive Summary
Hollis-Eden Pharmaceuticals' immune regulating hormone product HE2100 could be approved as a radioprotectant in the next one to three years, Chairman Richard Hollis said